Patents by Inventor David Gueyrard

David Gueyrard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FLUORESCENT PROBE AND APPLICATIONS THEREOF
    Publication number: 20220390458
    Abstract: The invention relates a fluorescent compound of formula I: wherein A is selected from P, P?O and N; ·R1 is a residue comprising an oxygen atom·R2 is a residue comprising an oxygen atom, or a halogen, ·R3, R4 and R5 are alkyls, possibly substituted or a salt or a solvate thereof. The compound is useful as a fluorescent probe sensitive to membrane fluidity and for diagnosing cancer.
    Type: Application
    Filed: September 22, 2020
    Publication date: December 8, 2022
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE CLAUDE BERNARD LYON 1, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE LYON, CPE LYON FORMATION CONTINUE ET RECHERCHE pouvant être précédée ou suivie par CPE LYON FCR, CENTRE LEON BERARD, HOSPICES CIVILS DE LYON
    Inventors: Thierry GRANJON, Ofelia MANITI, Olivier MARCILLAT, Peter GOEKJIAN, Mouhedine CHENIOUR, Arnaud VIGNERON, David GUEYRARD, Sébastien IBANEZ
  • Alpha-carbolines for the treatment of cancer
    Patent number: 9428500
    Abstract: The present invention relates to inhibitors of the oncogenic protein kinase ALK of formula (I) as herein described and pharmaceutical compositions thereof, as well as to key intermediates towards their synthesis. The compounds of formula (I) are useful in the preparation of a medicament, in particular for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: August 30, 2016
    Assignees: UNIVERSITA DEGLI STUDI DI MILANO—BICOCCA, UNIVERSITE DE GENEVE, UNIVERSITE CLAUDE BERNARD—LYON
    Inventors: Carlo Gambacorti-Passerini, Luca Mologni, Leonardo Scapozza, William Bisson, Shaheen Ahmed, Peter Goekjian, Sébastien Tardy, Alexandre Orsato, David Gueyrard, Joseph Benoit
  • ALPHA-CARBOLINES FOR THE TREATMENT OF CANCER
    Publication number: 20150105554
    Abstract: The present invention relates to inhibitors of the oncogenic protein kinase ALK of formula (I) as herein described and pharmaceutical compositions thereof, as well as to key intermediates towards their synthesis. The compounds of formula (I) are useful in the preparation of a medicament, in particular for the treatment of cancer.
    Type: Application
    Filed: May 10, 2013
    Publication date: April 16, 2015
    Inventors: Carlo Gambacorti-Passerini, Luca Mologni, Leonardo Scapozza, William Bisson, Shaheen Ahmed, Peter Goekjian, Sébastien Tardy, Alexandre Orsato, David Gueyrard, Joseph Benoit
  • Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl
    Patent number: 8895744
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in the description, to their pharmaceutical compositions and use thereof for the treatment of cancer expressing oncogenic ALK protein, particularly anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma (DLBCL), inflammatory myofibroblastic tumors (IMT) and non-small cell lung cancer (NSCLC).
    Type: Grant
    Filed: August 27, 2009
    Date of Patent: November 25, 2014
    Assignees: Universita' Degli Studi di Milano-Bicocca, Universite' de Geneve, Universite' Claude Bernard de Lyon 1
    Inventors: Carlo Gambacorti Passerini, Luca Mologni, Leonardo Scapozza, Shaheen Ahmed, Peter G. Goekjian, David Gueyrard, Florence Popowycz, Benoit Joseph, Cedric Schneider, Pierre Garcia
  • ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL
    Publication number: 20110281862
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in the description, to their pharmaceutical compositions and use thereof for the treatment of cancer expressing oncogenic ALK protein, particularly anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma (DLBCL), inflammatory myofibroblastic tumours (IMT) and non-small cell lung cancer (NSCLC).
    Type: Application
    Filed: August 27, 2009
    Publication date: November 17, 2011
    Applicants: Universita' Degli Studi di Milano - Bicocca, Universite' Claude Bernard de Lyon 1, Universite' de Geneve
    Inventors: Carlo Gambacorti Passerini, Luca Mologni, Leonardo Scapozza, Shaheen Ahmed, Peter G. Goekjian, David Gueyrard, Florence Popowycz, Benoit Joseph, Cedric Schneider, Pierre Garcia
  • ANTIPROLIFERATIVE COMPOUNDS AND THERAPEUTIC USES THEREOF
    Publication number: 20110112110
    Abstract: Inhibitors of the oncogenic tyrosine kinase ALK and of the Bcr-Abl mutant T315I Bcr-Abl, pharmaceutical compositions containing the same and their use for the treatment of hyper-proliferative diseases.
    Type: Application
    Filed: March 30, 2009
    Publication date: May 12, 2011
    Applicants: UNIVERSITA' DEGLISTUDI DI MILANO- BICOCCA, UNIVERSITE ' DE GENEVE, UNIVERSITE ' CLAUDE BERNARD DE LYON 1
    Inventors: Carlo Gambacorti Passerini, Rosalind Helen Gunby, Alfonso Zambon, Leonardo Scapozza, Shaheen Ahmed, Peter G. Goekjian, David Gueyrard, Florence Popowycz, Cerric Schneider